Stock Taper
SCREENER COMPARE ANY 2 STOCKS
XNCR
XENCOR, INC.
NASDAQ
$26.06
▼ DOWN 9.76% (-2.82)

KEY STATISTICS

Market Cap$1.93 B
52w High$30.61
52w Low$7.91
Dividend Yield—
Frequency—
P/E-12.01
Volume2.05M
Shares Out.74.14M

COMPANY

LEADERSHIP

Bassil I. Dahiyat
CHIEF EXECUTIVE
Bassil I. Dahiyat

COMPENSATION 2026

Salary$742,800
Stock Awards$1,552,892
Incentive Plan Pay$490,248
All Other Comp.$8,247
Total$5,521,205

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 3, 2013
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
260

PRICE TARGET

Target High$44.00
Target Low$20.00
Target Median$27.00
Target Consensus$30.33

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$60.42M
NOV
4
WED

PRICE

$26.06 ▼ DOWN 9.76% (−$2.82)
$26.00$27.00$28.00$29.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM26.06

About Xencor, Inc.

https://www.xencor.com ↗

Xencor, Inc. is a Monrovia-based biopharma company developing engineered monoclonal antibodies and cytokine therapeutics for cancer, autoimmune diseases, and infectious conditions, with multiple drugs in various clinical trial phases.

INDUSTRY

Biotechnology

A PRODUCT XENCOR, INC. IS KNOWN FOR

Vudalimab (XmAb819)
Vudalimab (XmAb819)

Vudalimab is an investigational bispecific antibody targeting PD-1 and CTLA-4, in clinical development for advanced solid tumors like kidney cancer, and is a key part of Xencor's oncology pipeline.

COMPETITORS

COMPETITOR
AZN COMPARE
MGNX COMPARE
REGN COMPARE
ZYME COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Royalty$21M $22.44M ▲$4.42M ▼$41.22M ▲
Milestone— $5.8M — $10M ▲
License— — $100K —

ETFS HOLDING THIS STOCK

ETFS HOLDING
172
LISTED HERE
26
RANKED BY POSITION SIZE
XSMC.TO
0.12% · 4.5M
VTS.AX
0.00% · 2.3M
XBI
0.50% · 2.1M
SCHA
0.04% · 349.7K
DFAC
0.01% · 206.9K
AVSC
0.15% · 159.9K
FESM
0.06% · 145.2K
PRFZ
0.12% · 120.3K
TMSL
0.10% · 105.3K
SBIO
0.98% · 91.2K
LABU
0.34% · 75.2K
XRS2.DE
0.06% · 63.7K
ETLI.DE
5.74% · 48.2K
ISMD
0.35% · 42.3K
CN
CNCR
3.37% · 41.9K
RSSL
0.06% · 33.1K
BBC
1.40% · 25.4K
GSSC
0.04% · 15.3K
RFLR
0.21% · 7.7K
ZSML.TO
0.12% · 7.1K
ESSC
0.31% · 5.9K
URTY
0.02% · 2.8K
TILT
0.00% · 2.3K
VETS
0.05% · 1.2K
USFMDN.MX
0.00% · 217
FVI
0.02% · 138

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
321
TOP 12 OF 321 · RANKED BY POSITION SIZE
Blackrock, Inc.
13.7M sh · $219.79M
Blackrock Inc.
11.1M sh · $210.18M
Primecap Management Co/Ca/
10.7M sh · $125.22M
Vanguard Group Inc
7.2M sh · $109.7M
Bvf Inc/Il
7.1M sh · $114.85M
Rtw Investments, LP
6.8M sh · $109.12M
Ecor1 Capital, LLC
6.1M sh · $72.08M
Ra Capital Management, L.P.
5.3M sh · $84.92M
State Street Corp
5.0M sh · $79.76M
Tcg Crossover Management, LLC
2.5M sh · $39.48M
Price T Rowe Associates Inc /Md/
2.4M sh · $37.94M
Geode Capital Management, LLC
1.9M sh · $30.93M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR
Klencke Barbara
Purchase · 20.6K shares
2026-06-16
★
DIRECTOR
Montgomery Alan Bruce
Purchase · 10.3K shares
2026-06-16
★
DIRECTOR
GORMAN KEVIN CHARLES
Purchase · 20.6K shares
2026-06-16
★
DIRECTOR
SIMPSON TODD E
Purchase · 20.6K shares
2026-06-16

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 2
OVERWEIGHT 2
NEUTRAL 2
BUY 1
7 GRADES IN THE LAST 12 MONTHS
Wedbush OUTPERFORM Cantor Fitzgerald OVERWEIGHT RBC Capital OUTPERFORM Truist Securities BUY JP Morgan NEUTRAL Barclays OVERWEIGHT B of A Securities NEUTRAL

SECTORS PEERS

PEERPRICE
TNGX$23.34COMPARE
NRIX$26.21COMPARE
KOD$37.72COMPARE
URGN$43.62COMPARE
NKTR$72.52COMPARE
ANAB$56.28COMPARE
PHAT$9.18COMPARE
BBOT$8.74COMPARE